Journal
ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA
Volume 27, Issue 4, Pages 497-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.coms.2015.06.002
Keywords
Bisphosphonates; Denosumab; Antiremodeling agents; ONJ
Categories
Ask authors/readers for more resources
In the late 1990s and the early 2000s, bisphosphonates had become the clinical pillar of excellence for treating metabolic bone disease, and thus their connection with osteonecrosis of the jaw (ONJ) caused significant concern. Over the past decade, progress has been made in understanding what is now referred to as medication-related ONJ (MRONJ), because of its connections to agents other than bisphosphonates, although in many respects the progress has been slow. This review highlights the key basic science and translational (animal) studies in the area of MRONJ and suggests areas of focus as the field moves into the next decade.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available